Nav: Home

Unexpected regulation of transcription factors critical to development

October 10, 2017

AMHERST, Mass. - A team of developmental biologists at the University of Massachusetts Amherst led by Dominique Alfandari, with others at MIT, report in a new paper that they have for the first time described how two transcription factors that are "absolutely essential for human development" are regulated by a cell surface metalloprotease known as ADAM13. The discovery adds to knowledge of how cells migrate in vertebrate embryos, how stem cells differentiate and how cancer cells metastasize.

ADAM13 belongs to a group of proteins called proteases that cut other proteins to change their function. Alfandari says, "Five years ago we discovered that ADAM metalloproteases control gene expression in a cell; no one had done that before. In this new paper, we describe the details of the mechanism by which the ADAM13 protein on the cell surface can affect gene expression in the nucleus, which is remarkable."

"We found that ADAM13 has to work with a series of other proteins and two transcription factors, tfap2- and arid3a. We've described every step they take and how they are changed to get the work done. Arid3a shuttles between ADAM13 on the surface and genes in the nucleus. We've seen that some ADAMs can do this but, for example, ADAM9 can't do it at all," the molecular biologist adds. Details appear now in the online, open-access journal eLIFE.

In studies supported by the NIH's National Institute of Dental and Craniofacial Research, Alfandari and colleagues including co-investigator Helene Cousin and first author and postdoctoral researcher Vikram Khedgikar, are well known for tracking individual cells in frog embryos to learn how the ADAM13 protease controls proteins in the cranial neural crest to form the jaw and face. Cranial neural crest cell migration is common to all vertebrate embryos including humans, and defects in their production or migration lead to severe facial malformations.

After many years of this work, Alfandari and colleagues are now getting more into the detail of what the ADAM family of proteins can do, he notes. "What is exciting about that is we've shown that ADAM13, which is one of more than 30 members of this family, controls two essential transcription factors that bind to DNA to turn on genes."

He explains that arid3a in humans controls cell-fate decisions, that is, it directs uncommitted stem cells to differentiate from a naïve state to a cell that knows its job. In this role, arid3a can be thought of as an "anti-stem-cell factor," because it shuts down the stem cell's ability to remain naïve. Alfandari quips, "It kicks the kids out of home and forces them to go to school and learn a trade."

A special role of arid3a in forcing the cell to specialize has implications for cancer, he adds. When cells differentiate they often stop dividing; they rarely do both. By forcing differentiation, arid3a suppresses cell division. He explains, "In a tumor, this means arid3a forces tumor cells to stay in place and perform work rather than dividing. They are more benign, tending to stay in place and not metastasize." Thus, the prognosis for a patient with a tumor that has a lot of arid3a in it is better than one that has little arid3a, because with less, they proliferate more.

Alfandari adds, "Perhaps it may give us a new tool to control tumors, if you can control ADAM activity from outside of the cell, you could control arid3a as well. This is long-term, I'm dreaming of what could happen. We don't know yet if ADAM can play a role in this way to control cancer, but it is a new possibility."

As for tfap2-, in all species studied so far it controls the cells at the border of the neural plate in the embryo, which go on to form all of the sensory organs for hearing, vision and smell, plus all the cranio-facial structures, so "tfap2- pretty much defines this group of cells during vertebrate evolution," the lab director points out.

"For our work this is very important because it helps us understand how neural crest cells acquire their specialization and learn how and where to move. It also suggests that ADAM proteins in other kinds of cells may regulate similar processes."

The molecular biologist says that ADAM13 has been thought of as "a low-key player, it was not thought to be critical." Indeed, he thinks of ADAM proteins as a fine-tuning mechanism, like the coach on the sidelines of a football game. "If you lose the coach, the team can continue to function even if less efficient. If an embryo is missing ADAM13, it can survive, but with birth defects."

However, the transcription factors arid3a and tfap2- are far more important, more akin to a quarterback. "If you lose the quarterback, the team can't go on," he says. "If you lost arid3a and tfap2-alpha, these are absolutely critical for the embryo and without them it cannot survive."

In the future, Alfandari says, his lab will continue to define the parts of ADAM13 and arid3a that communicate with each other and how arid3a shuttles between ADAM on the cell surface and genes in the nucleus. "Our goal is to figure out the specific protein sequences that control arid3a," he notes. "That will take another five years."

University of Massachusetts at Amherst

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Anticancer: A New Way of Life
by David Servan-Schreiber MD PhD (Author)

The Emperor of All Maladies: A Biography of Cancer
by Siddhartha Mukherjee (Author)

The Truth about Cancer: What You Need to Know about Cancer's History, Treatment, and Prevention
by Ty M Bollinger (Author)

The Cancer-Fighting Kitchen, Second Edition: Nourishing, Big-Flavor Recipes for Cancer Treatment and Recovery
by Rebecca Katz (Author), Mat Edelson (Author)

The Cancer Revolution: A Groundbreaking Program to Reverse and Prevent Cancer
by Leigh Erin Connealy (Author)

F*ck Cancer: A totally inappropriate self-affirming adult coloring book (Totally Inappropriate Series) (Volume 4)
by Jen Meyers (Author)

Radical Remission: Surviving Cancer Against All Odds
by Kelly A. Turner PhD (Author)

The Metabolic Approach to Cancer: Integrating Deep Nutrition, the Ketogenic Diet, and Nontoxic Bio-Individualized Therapies
by Dr. Nasha Winters ND FABNO L.Ac Dipl.OM (Author), Jess Higgins Kelley MNT (Author), Kelly Turner (Foreword)

Cancer: 50 Essential Things to Do: 2013 Edition
by Greg Anderson (Author)

Outside the Box Cancer Therapies: Alternative Therapies That Treat and Prevent Cancer
by Dr. Mark Stengler (Author), Dr. Paul Anderson (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Why We Hate
From bullying to hate crimes, cruelty is all around us. So what makes us hate? And is it learned or innate? This hour, TED speakers explore the causes and consequences of hate — and how we can fight it. Guests include reformed white nationalist Christian Picciolini, CNN commentator Sally Kohn, podcast host Dylan Marron, and writer Anand Giridharadas.
Now Playing: Science for the People

#482 Body Builders
This week we explore how science and technology can help us walk when we've lost our legs, see when we've gone blind, explore unfriendly environments, and maybe even make our bodies better, stronger, and faster than ever before. We speak to Adam Piore, author of the book "The Body Builders: Inside the Science of the Engineered Human", about the increasingly amazing ways bioengineering is being used to reverse engineer, rebuild, and augment human beings. And we speak with Ken Thomas, spacesuit engineer and author of the book "The Journey to Moonwalking: The People That Enabled Footprints on the Moon" about...